Key clinical point: Administration of a single dose of SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) led to seroconversion and T-cell response in most patients with chronic-phase chronic myeloid leukemia (CML-CP), with neutralizing antibody responses in all.
Major finding: After 3 weeks of BNT162b2 administration, anti-Spike immunoglobulin G and neutralizing antibodies were observed in 87.5% and 100% of patients, respectively. A memory T-cell response was observed in 93.3% of patients, with a polyfunctional cytokine response in either CD4 + or CD8 + T cells in 80% of patients.
Study details: Findings are from an analysis of 16 adult patients with CML-CP who received the first injection of 30 mg BNT162b2.
Disclosures: This study was funded by King’s Together Rapid COVID-19 Call Award, Huo Family Foundation Award, Chronic Disease Research Foundation award, Wellcome Trust Investigator Award, MRC-KCL Doctoral Training Partnership in Biomedical Sciences, Fondation Dormeur (Vaduz), Blood Cancer UK, LifeArc, Cancer Research UK, and King’s Health Partners Centre.
Source: Harrington P et al. Br J Haematol. 2021 June 3. doi: 10.1111/bjh.17568 .